Arkolith/Insider Trading/TERN/Form 4

Burroughs Amy L.

Chief Executive Officer, DirectorTerns Pharmaceuticals, Inc. (TERN) · full profile →Form 4 · filed Jan 6, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$2.7M
Net Open-Market Flow
-$2.7M
Transactions
5
3 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 5, 2026Sell(S)71K$38.10$2.7M139K
Jan 5, 2026Option exercise(M)150K——210K
Jan 2, 2026Option exercise(M)22K$4.64$100K60K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jan 5, 2026Option exercise(M)150K—$00
Jan 2, 2026Option exercise(M)22K—$01.1M

Transaction Codes

S
Open-market sale
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001872564-26-000002) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML